Fig. 3

Distribution of DRG based costs for cases and controls during their first hospitalization in 2012. DRG cost weights are the basis for a considerable share (40%) of hospital reimbursement in Norway, and hence, an important proxy for costs per patient, however inaccurate. Due to limited access to micro costing data for patients in this study, DRG cost weights were used to estimate costs per hospital stay, although these costs are potentially an underestimate of the actual economic burden caused by MRSA to hospitals